secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001193125-25-060850
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBVT: FDA agrees on safety data for Viaskin BLA in 4-7 yr olds; cash only into Apr 2025
--------------------------------------------------------------------------------

- FDA aligns: safety data from VITESSE Phase 3 and OLE sufficient for BLA; no COMFORT Children study needed; BLA filing 1H 2026, potential launch acceleration ~1 year.
- VITESSE Phase 3 topline results on track for Q4 2025; 654 participants enrolled, largest peanut allergy trial in 4-7 age group.
- Cash $32.5M at Dec 31, 2024 (vs $141.4M); net loss $113.9M ($1.17 diluted EPS); operating expenses $120.7M.
- Going concern: cash expected only into April 2025; company actively seeking additional capital and reviewing financing options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312525060850/0001193125-25-060850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312525060850/d932759d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-060850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer